Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Biomarker-Guided Trial to Evaluate ALRN-6924 in Combination with IBRANCE (Palbociclib) in MDM2-Amplified Solid Tumors

Trial Profile

A Biomarker-Guided Trial to Evaluate ALRN-6924 in Combination with IBRANCE (Palbociclib) in MDM2-Amplified Solid Tumors

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ALRN 6924 (Primary) ; Palbociclib (Primary)
  • Indications Liposarcoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aileron Therapeutics
  • Most Recent Events

    • 09 Aug 2019 Planned number of patients changed from 25 to 35 as per the Aileron Therapeutics media release.
    • 06 Aug 2019 According to the Aileron Therapeutics media release, the company expect to present results from all patients in the second quarter of 2020.
    • 06 Aug 2019 According to the Aileron Therapeutics media release, the company expect to fully enroll targeted 25 patients by the end of September 2019, and as the combination has been well tolerated, the company plans to expand enrolment from 25 to 35 patients, focusing on indications outside of liposarcoma to determine the broader applicability of this combination therapy in other MDM2-amplified cancers.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top